Table 1.
Patient Characteristics at Baseline and 12 Months After Intravitreous Injection of Aflibercept
| Pachychoroid Neovasculopathy | Neovascular AMD | |||||
|---|---|---|---|---|---|---|
| Baseline | 12 Months | P value | Baseline | 12 Months | P value | |
| Age, years | 74.4 ± 8.1 | 78.5 ± 7.3 | ||||
| Sex (male/female) | 22/5 | 37/26 | ||||
| Number of eyes | 27 | 63 | ||||
| BCVA, logMAR (range) | 0.28 (0.13–0.44) | 0.14 (0.11–0.27) | 0.001* | 0.40 (0.31–0.50) | 0.29 (0.19–0.39) | < 0.001* |
| GLD, µm (range) | 3294 ± 1649 (2642–3947) | 3033 ± 1729 (2350–3717) | 0.090* | 3885 ± 1739 (3447–4323) | 3356 ± 1569 (2961–3751) | 0.001* |
| Lesion size, mm2 (range) | 5.17 ± 3.92 (3.62–6.72) | 5.01 ± 4.76 (3.13–6.89) | 0.811* | 9.95 ± 13.18 (6.63–13.27) | 6.08 ± 5.46 (4.70–7.45) | 0.013* |
| CRT, µm (range) | 346 ± 132 (294–399) | 197 ± 56 (174–219) | < 0.001* | 380 ± 180 (335–426) | 206 ± 119 (176–236) | < 0.001* |
| SFCT, µm (range) | 338 ± 66 (312–364) | 303 ± 81 (271–335) | < 0.001* | 223 ± 90 (200–246) | 192 ± 88 (170–215) | < 0.001* |
| Intact foveal ELM (±) | 13/14 | 21/6 | 0.008** | 18/45 | 30/33 | 0.004** |
| Intact foveal EZ (±) | 1/26 | 12/15 | 0.001** | 5/58 | 13/50 | 0.021** |
| Vitreoretinal adhesion (±) | 5/22 | 3/24 | 0.500** | 16/47 | 12/51 | 0.289** |
| Presence of polyps (±) | 13/14 | 5/22 | 0.039** | 32/31 | 14/49 | < 0.001** |
Notes: Data are presented as mean ± standard deviation or number of patients. *Paired t-test, **McNemar’s test.
Abbreviations: AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; logMAR, logarithm of minimal angle of resolution; GLD, greatest lesion diameter; CRT, central retinal thickness; SFCT, subfoveal choroidal thickness; ELM, external limiting membrane; EZ, ellipsoid zone.